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Inhaled medication and inhalation devices for lung disease in patients with
cystic fibrosis: Three areas for future research
Which areas to target? Which particle size to deliver? Which device to use?Sir,
We have read the European consensus article about inhaled
medication and inhalation devices in CF therapy with great
interest and would like to congratulate the authors on a great
achievement [1]. The aim of inhaled antibiotic therapy in CF is
to reach the best clinical response with a minimum of side
effects. On three important topics regarding inhaled antibiotics
no recommendations were made. With this letter we would like
to put these issues forward as areas for future research, both
bench- and bed-side, as well as to hypothesize on the answers.Which areas to target?
Cystic fibrosis is thought to be a disease starting in the small
airways on the basis of infant pulmonary function tests [2] and
imaging studies [3]. Pseudomonas aeruginosa (Psa) is regarded
as the most important pathogen in adult CF patients. A recent
study demonstrates that Psa is present in both conductive and
respiratory airways [4]. Psa is very capable to develop
resistance to virtually all anti-pseudomonal agents through the
selection of genetic mutations [1].
Aminoglycosides are the most frequently used inhaled
antibiotics in CF lung disease and they need high peak levels
(far above the Minimal Inhibitory Concentration, MIC) to make
use of the reported post-antibiotic effect of this class of drugs.
Efficacy of aminoglycosides is predicted best by the peak
concentration (Cmax) to MIC ratio [5,6] and a Cmax/MIC ratio
greater than 10 is advised. A concentration gradient can be a risk
for resistance development and the lowest drug concentration
obtained in the lungs must be sufficiently high above MIC.
According to criteria from the European Society of Clinical
Microbiology and Infectious Diseases (EUCAST, www.eucast.
org) Pa strains with MICb2 mg/L for tobramycin are considered
sensitive to this type of antibiotic. Thus, to obtain an effective
therapy, based on MIC and advised Cmax/MIC ratio, tobramycin
concentrations of N20 mg/L in all airways may be necessary.1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.03.009Which particle size to deliver?
In patients with stable asthma, Usmani et al. showed in a
radio-isotope study that about 50% (+/− 5%) of the real dose of
monodisperse particles in the size range between 1.5 and 6
micron can be deposited in the lungs. These deposition fractions
were reached with a slow inhalation (mean of 30.8 L/min),
followed by a breathhold period [7]. The other 50% of the dose
is not deposited in the lungs, but either predominantly exhaled
(especially the smaller particles) or deposited in the oropharynx.
There is an increase in peripheral lung deposition from 10 to
25% of the real dose for particles with decreasing particle size
from 6, to 1.5μm. So, smaller particles can give considerably
higher peripheral lung deposition which is in agreement with
prediction from computational lung deposition studies.
Airway generations (gens) 17 to 23, frequently referred to as
the respiratory airways, contribute more than 95% to the total
airway surface area. In contrast, the transitional airways (gens
12–16) add only 4% and the conducting airways (gens 1–11)
cover less than 1% to the total area [8]. Although the definitions
used by Usmani et al. in their study for central, intermediate and
peripheral airways are not completely comparable to these
definitions for conducting, transitional and respiratory airways,
it is clear that differences in the mass median aerodynamic
diameter (MMAD) result in extreme differences between drug
concentrations in different lung regions. Only approx. 25% of
the real dose of 1.5μm particles deposits on 95% of the total
lung surface area (in the peripheral lung) versus 31% of the real
dose on the complementary 5% of the total surface area (in the
central and intermediate lung). This yields a difference in
concentration almost by a factor 25. For larger particles or
higher flow rates, the differences are even greater. A fall in
concentration from upper to lower lung is therefore inevitable,
but particles in the aerodynamic size range between 1 and 2μm
yield clearly more homogeneous drug concentrations within the
whole lung than particles in the size range between 2 and 4 μm,
or even larger. Therefore, fine particles (1–2μm) seem
preferable for design of future delivery devices for antibioticsd by Elsevier B.V. All rights reserved.
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manoeuvre (inspiratory peak flow rate ≤30 L/min).
Which device to use?
On the basis of the small airway involvement in CF and the
exponentially increasing surface area of the airways towards the
alveoli, the peripheral airways should be targeted for inhaled
antibiotics. Targeting should be with small particles (1–2μm)
and slow inhalation (30 L/min). The aerosol administration
devices for antibiotics in CF should be selected with the
objective to fulfil these requirements.
The authors describe studies with various administration
devices in respect of total lung dose and mention values ranging
from 3 to 73% [1]. Differences in the site of deposition may be
expected from using the Pari LC Plus with a ‘suitable’
compressor for TOBI (Pari TurboBoy N) or the eFlow rapid.
Under laboratory conditions (suction rate 30 L/min), the
MMAD's from these devices are 2.8 and 3.5μm respectively
[9]. Also the subfractions of fine particles (particularly 1–2
micron) are different (22.6 and 14.4% of the emitted dose at
30 L/min respectively). This will result in a different distribu-
tion over the airways (even if total lung deposition is the same)
from both devices [5]. A larger difference may result when the
average inspiratory flow rate through the eFlow is higher than
that through the LC Plus (peak inspiratory flow rates may vary
between 17 and 90 L/min for adult patients breathing through a
nebuliser device [10]). The relevance of such variations to the
efficacy of the treatment has to be investigated in clinical studies
by comparison of the effect of the same drug administered with
different MMAD's and different flow rates. A breathhold period
after inhalation is important when using a DPI in order to
achieve significant deposition by sedimentation. When the
prerequisites of MMAD and flow manoeuvre are considered,
both a dry powder inhaler or a nebuliser-system may be
appropriate.
Yours sincerely,
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